{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:25:25Z","timestamp":1790677525145,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Mirati Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00262-017-2091-y","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T15:21:22Z","timestamp":1510240882000},"page":"381-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["The class I\/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy"],"prefix":"10.1007","volume":"67","author":[{"given":"David","family":"Briere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niranjan","family":"Sudhakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Hallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars D.","family":"Engstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrah","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andressa L.","family":"Sodr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,9]]},"reference":[{"issue":"17","key":"2091_CR1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627\u20131639","journal-title":"N Engl J Med"},{"issue":"2","key":"2091_CR2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135","journal-title":"N Engl J Med"},{"issue":"5","key":"2091_CR3","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","volume":"44","author":"MK Callahan","year":"2016","unstructured":"Callahan MK, Postow MA, Wolchok JD (2016) Targeting T cell co-receptors for cancer therapy. Immunity 44(5):1069\u20131078","journal-title":"Immunity"},{"issue":"3","key":"2091_CR4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ et al (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16(3):257\u2013265","journal-title":"Lancet Oncol"},{"issue":"1","key":"2091_CR5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2013.03.002","volume":"153","author":"LA Garraway","year":"2013","unstructured":"Garraway LA, Lander ES (2013) Lessons from the cancer genome. Cell 153(1):17\u201337","journal-title":"Cell"},{"issue":"7484","key":"2091_CR6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR et al (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505(7484):495\u2013501","journal-title":"Nature"},{"issue":"9","key":"2091_CR7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S et al (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375(9):819\u2013829","journal-title":"N Engl J Med"},{"issue":"10","key":"2091_CR8","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1073\/pnas.1011037108","volume":"108","author":"AJ Christiansen","year":"2011","unstructured":"Christiansen AJ, West A, Banks KM, Haynes NM, Teng MW, Smyth MJ et al (2011) Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci USA 108(10):4141\u20134146","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2091_CR9","doi-asserted-by":"crossref","first-page":"e30815","DOI":"10.1371\/journal.pone.0030815","volume":"7","author":"L Shen","year":"2012","unstructured":"Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P et al (2012) Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS ONE 7(1):e30815","journal-title":"PLoS ONE"},{"issue":"12","key":"2091_CR10","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","volume":"3","author":"DM Woods","year":"2015","unstructured":"Woods DM, Sodre AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J (2015) HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol Res 3(12):1375\u20131385","journal-title":"Cancer Immunol Res"},{"issue":"7645","key":"2091_CR11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature21409","volume":"543","author":"JL Guerriero","year":"2017","unstructured":"Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S et al (2017) Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature 543(7645):428\u2013432","journal-title":"Nature"},{"issue":"6","key":"2091_CR12","doi-asserted-by":"crossref","first-page":"e1164919","DOI":"10.1080\/2162402X.2016.1164919","volume":"5","author":"M Kroesen","year":"2016","unstructured":"Kroesen M, Bull C, Gielen PR, Brok IC, Armandari I, Wassink M et al (2016) Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma. Oncoimmunology 5(6):e1164919","journal-title":"Oncoimmunology"},{"issue":"9","key":"2091_CR13","doi-asserted-by":"crossref","first-page":"a019505","DOI":"10.1101\/cshperspect.a019505","volume":"8","author":"SB Baylin","year":"2016","unstructured":"Baylin SB, Jones PA (2016) Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol 8(9):a019505","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"2091_CR14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","volume":"128","author":"T Kouzarides","year":"2007","unstructured":"Kouzarides T (2007) Chromatin modifications and their function. Cell 128(4):693\u2013705","journal-title":"Cell"},{"issue":"1","key":"2091_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1):1\u201310","journal-title":"Immunity"},{"issue":"7378","key":"2091_CR16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480(7378):480\u2013489","journal-title":"Nature"},{"issue":"4","key":"2091_CR17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264","journal-title":"Nat Rev Cancer"},{"issue":"6230","key":"2091_CR18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124\u2013128","journal-title":"Science"},{"issue":"23","key":"2091_CR19","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189\u20132199","journal-title":"N Engl J Med"},{"issue":"1","key":"2091_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14712\/fb2005051010001","volume":"51","author":"J Bubenik","year":"2005","unstructured":"Bubenik J (2005) MHC class I down regulation, tumour escape from immune surveillance and design of therapeutic strategies. Folia Biol (Praha) 51(1):1\u20132","journal-title":"Folia Biol (Praha)"},{"issue":"3","key":"2091_CR21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/jcp.10290","volume":"195","author":"A Garcia-Lora","year":"2003","unstructured":"Garcia-Lora A, Algarra I, Garrido F (2003) MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 195(3):346\u2013355","journal-title":"J Cell Physiol"},{"issue":"12","key":"2091_CR22","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood.V96.12.3847","volume":"96","author":"T Maeda","year":"2000","unstructured":"Maeda T, Towatari M, Kosugi H, Saito H (2000) Up-regulation of costimulatory\/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96(12):3847\u20133856","journal-title":"Blood"},{"issue":"12","key":"2091_CR23","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.4049\/jimmunol.165.12.7017","volume":"165","author":"WJ Magner","year":"2000","unstructured":"Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C et al (2000) Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 165(12):7017\u20137024","journal-title":"J Immunol"},{"issue":"23","key":"2091_CR24","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.1158\/0008-5472.CAN-05-0599","volume":"65","author":"S Skov","year":"2005","unstructured":"Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N (2005) Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 65(23):11136\u201311145","journal-title":"Cancer Res"},{"issue":"5","key":"2091_CR25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CMR.0b013e328364c0ed","volume":"23","author":"DM Woods","year":"2013","unstructured":"Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C et al (2013) The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res 23(5):341\u2013348","journal-title":"Melanoma Res"},{"issue":"7528","key":"2091_CR26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563\u2013567","journal-title":"Nature"},{"issue":"7528","key":"2091_CR27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528):558\u2013562","journal-title":"Nature"},{"issue":"26","key":"2091_CR28","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443\u20132454","journal-title":"N Engl J Med"},{"issue":"328","key":"2091_CR29","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8(328):328rv4","journal-title":"Sci Transl Med"},{"issue":"4","key":"2091_CR30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12(4):237\u2013251","journal-title":"Nat Rev Cancer"},{"issue":"32","key":"2091_CR31","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1073\/pnas.1410626111","volume":"111","author":"K Kim","year":"2014","unstructured":"Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL et al (2014) Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci USA 111(32):11774\u201311779","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"2091_CR32","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-15-2584","volume":"22","author":"H Zheng","year":"2016","unstructured":"Zheng H, Zhao W, Yan C, Watson CC, Massengill M, Xie M et al (2016) HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin Cancer Res 22(16):4119\u20134132","journal-title":"Clin Cancer Res"},{"issue":"229","key":"2091_CR33","doi-asserted-by":"crossref","first-page":"ra45","DOI":"10.1126\/scisignal.2002873","volume":"5","author":"UH Beier","year":"2012","unstructured":"Beier UH, Wang L, Han R, Akimova T, Liu Y, Hancock WW (2012) Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+\u00a0regulatory T cell function through shared and isoform-specific mechanisms. Sci Signal 5(229):ra45","journal-title":"Sci Signal"},{"issue":"2","key":"2091_CR34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1021\/jm200773h","volume":"55","author":"JH Kalin","year":"2012","unstructured":"Kalin JH, Butler KV, Akimova T, Hancock WW, Kozikowski AP (2012) Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+\u00a0T-regulatory cells. J Med Chem 55(2):639\u2013651","journal-title":"J Med Chem"},{"issue":"10","key":"2091_CR35","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1128\/MCB.05155-11","volume":"31","author":"EF Zoeten de","year":"2011","unstructured":"de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H et al (2011) Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol 31(10):2066\u20132078","journal-title":"Mol Cell Biol"},{"issue":"11","key":"2091_CR36","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1021\/acsmedchemlett.5b00303","volume":"6","author":"MC Segretti","year":"2015","unstructured":"Segretti MC, Vallerini GP, Brochier C, Langley B, Wang L, Hancock WW et al (2015) Thiol-based potent and selective HDAC6 inhibitors promote tubulin acetylation and T-regulatory cell suppressive function. ACS Med Chem Lett 6(11):1156\u20131161","journal-title":"ACS Med Chem Lett"},{"issue":"3","key":"2091_CR37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ni.2526","volume":"14","author":"JI Youn","year":"2013","unstructured":"Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P et al (2013) Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol 14(3):211\u2013220","journal-title":"Nat Immunol"},{"key":"2091_CR38","doi-asserted-by":"crossref","unstructured":"Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S et al (2017) Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clin Cancer Res 23(17):5187\u20135201","DOI":"10.1158\/1078-0432.CCR-17-0741"},{"issue":"11","key":"2091_CR39","doi-asserted-by":"crossref","first-page":"e0166438","DOI":"10.1371\/journal.pone.0166438","volume":"11","author":"B Egan","year":"2016","unstructured":"Egan B, Yuan CC, Craske ML, Labhart P, Guler GD, Arnott D et al (2016) An alternative approach to ChIP-Seq normalization enables detection of genome-wide changes in histone H3 lysine 27 trimethylation upon EZH2 inhibition. PLoS One 11(11):e0166438","journal-title":"PLoS One"},{"key":"2091_CR40","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1038\/ncomms3680","volume":"4","author":"CS Carlson","year":"2013","unstructured":"Carlson CS, Emerson RO, Sherwood AM, Desmarais C, Chung MW, Parsons JM et al (2013) Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun 4:2680","journal-title":"Nat Commun"},{"issue":"1\u20132","key":"2091_CR41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jim.2011.09.001","volume":"375","author":"H Robins","year":"2012","unstructured":"Robins H, Desmarais C, Matthis J, Livingston R, Andriesen J, Reijonen H et al (2012) Ultra-sensitive detection of rare T cell clones. J Immunol Methods 375(1\u20132):14\u201319","journal-title":"J Immunol Methods"},{"issue":"19","key":"2091_CR42","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","volume":"114","author":"HS Robins","year":"2009","unstructured":"Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O et al (2009) Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114(19):4099\u20134107","journal-title":"Blood"},{"issue":"10","key":"2091_CR43","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.molonc.2015.09.003","volume":"9","author":"I Kirsch","year":"2015","unstructured":"Kirsch I, Vignali M, Robins H (2015) T-cell receptor profiling in cancer. Mol Oncol 9(10):2063\u20132070","journal-title":"Mol Oncol"},{"issue":"11","key":"2091_CR44","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/intimm\/dxh326","volume":"17","author":"SD Chou","year":"2005","unstructured":"Chou SD, Khan AN, Magner WJ, Tomasi TB (2005) Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int Immunol 17(11):1483\u20131494","journal-title":"Int Immunol"},{"issue":"5","key":"2091_CR45","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00262-007-0402-4","volume":"57","author":"AN Khan","year":"2008","unstructured":"Khan AN, Gregorie CJ, Tomasi TB (2008) Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 57(5):647\u2013654","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2091_CR46","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/89810","volume":"2","author":"GW Beresford","year":"2001","unstructured":"Beresford GW, Boss JM (2001) CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter. Nat Immunol 2(7):652\u2013657","journal-title":"Nat Immunol"},{"issue":"2","key":"2091_CR47","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ni883","volume":"4","author":"K Masternak","year":"2003","unstructured":"Masternak K, Peyraud N, Krawczyk M, Barras E, Reith W (2003) Chromatin remodeling and extragenic transcription at the MHC class II locus control region. Nat Immunol 4(2):132\u2013137","journal-title":"Nat Immunol"},{"issue":"9","key":"2091_CR48","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.it.2006.07.007","volume":"27","author":"KL Wright","year":"2006","unstructured":"Wright KL, Ting JP (2006) Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 27(9):405\u2013412","journal-title":"Trends Immunol"},{"issue":"3","key":"2091_CR49","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.yjmcc.2008.10.023","volume":"46","author":"X Kong","year":"2009","unstructured":"Kong X, Fang M, Li P, Fang F, Xu Y (2009) HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells. J Mol Cell Cardiol 46(3):292\u2013299","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"2091_CR50","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/emboj\/21.6.1379","volume":"21","author":"K Masternak","year":"2002","unstructured":"Masternak K, Reith W (2002) Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation. EMBO J 21(6):1379\u20131388","journal-title":"EMBO J"},{"issue":"3","key":"2091_CR51","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1248\/bpb.32.480","volume":"32","author":"MI Niesen","year":"2009","unstructured":"Niesen MI, Blanck G (2009) Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. Biol Pharm Bull 32(3):480\u2013482","journal-title":"Biol Pharm Bull"},{"issue":"22","key":"2091_CR52","doi-asserted-by":"crossref","first-page":"8489","DOI":"10.1128\/MCB.20.22.8489-8498.2000","volume":"20","author":"C Spilianakis","year":"2000","unstructured":"Spilianakis C, Papamatheakis J, Kretsovali A (2000) Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes. Mol Cell Biol 20(22):8489\u20138498","journal-title":"Mol Cell Biol"},{"issue":"5168","key":"2091_CR53","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1126\/science.8016643","volume":"265","author":"V Steimle","year":"1994","unstructured":"Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B (1994) Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265(5168):106\u2013109","journal-title":"Science"},{"issue":"3","key":"2091_CR54","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.intimp.2013.02.004","volume":"16","author":"J Grzanka","year":"2013","unstructured":"Grzanka J, Leveson-Gower D, Golab K, Wang XJ, Marek-Trzonkowska N, Krzystyniak A et al (2013) FoxP3, Helios, and SATB1: roles and relationships in regulatory T cells. Int Immunopharmacol 16(3):343\u2013347","journal-title":"Int Immunopharmacol"},{"issue":"7528","key":"2091_CR55","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568\u2013571","journal-title":"Nature"},{"issue":"7","key":"2091_CR56","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1158\/0008-5472.CAN-15-2125","volume":"76","author":"KB Chiappinelli","year":"2016","unstructured":"Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB (2016) Combining Epigenetic and Immunotherapy to Combat Cancer. Cancer Res 76(7):1683\u20131689","journal-title":"Cancer Res"},{"issue":"3","key":"2091_CR57","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/j.seminoncol.2015.02.003","volume":"42","author":"A Covre","year":"2015","unstructured":"Covre A, Coral S, Di Giacomo AM, Taverna P, Azab M, Maio M (2015) Epigenetics meets immune checkpoints. Semin Oncol 42(3):506\u2013513","journal-title":"Semin Oncol"},{"key":"2091_CR58","doi-asserted-by":"crossref","first-page":"690901","DOI":"10.5402\/2012\/690901","volume":"2012","author":"PV Licciardi","year":"2012","unstructured":"Licciardi PV, Karagiannis TC (2012) Regulation of immune responses by histone deacetylase inhibitors. ISRN Hematol 2012:690901","journal-title":"ISRN Hematol"},{"issue":"9","key":"2091_CR59","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/ijc.28865","volume":"135","author":"CS Tellez","year":"2014","unstructured":"Tellez CS, Grimes MJ, Picchi MA, Liu Y, March TH, Reed MD et al (2014) SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. Int J Cancer 135(9):2223\u20132231","journal-title":"Int J Cancer"},{"issue":"3","key":"2091_CR60","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4161\/onci.18804","volume":"1","author":"AC West","year":"2012","unstructured":"West AC, Christiansen AJ, Smyth MJ, Johnstone RW (2012) The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects. Oncoimmunology 1(3):377\u2013379","journal-title":"Oncoimmunology"},{"issue":"4","key":"2091_CR61","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1535-7163.MCT-07-2026","volume":"7","author":"M Fournel","year":"2008","unstructured":"Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A et al (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7(4):759\u2013768","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2091_CR62","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s10495-008-0303-9","volume":"14","author":"O Kepp","year":"2009","unstructured":"Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L et al (2009) Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 14(4):364\u2013375","journal-title":"Apoptosis"},{"issue":"3","key":"2091_CR63","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.clim.2010.04.018","volume":"136","author":"T Akimova","year":"2010","unstructured":"Akimova T, Ge G, Golovina T, Mikheeva T, Wang L, Riley JL et al (2010) Histone\/protein deacetylase inhibitors increase suppressive functions of human FOXP3+\u00a0Tregs. Clin Immunol 136(3):348\u2013363","journal-title":"Clin Immunol"},{"issue":"11","key":"2091_CR64","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.1073\/pnas.0700298104","volume":"104","author":"B Li","year":"2007","unstructured":"Li B, Samanta A, Song X, Iacono KT, Bembas K, Tao R et al (2007) FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci USA 104(11):4571\u20134576","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2091_CR65","doi-asserted-by":"crossref","first-page":"948","DOI":"10.4161\/onci.20306","volume":"1","author":"L Shen","year":"2012","unstructured":"Shen L, Pili R (2012) Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. Oncoimmunology 1(6):948\u2013950","journal-title":"Oncoimmunology"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-2091-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2091-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2091-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T23:18:52Z","timestamp":1750979932000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-2091-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,9]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["2091"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-2091-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,9]]}}}